AOD-9604 Switching Reports: What Users Experience Moving To or From This Peptide

HealthRX.com

No published switching results exist for AOD-9604

Print or save as PDF

Key numbers

  • 500 microgram/kg/dayOral daily dose used in obese Zucker rats (animal study, not humans)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 15.8 gWeight gain of obese Zucker rats on oral AOD-9604 over 19 days (controls 35.6 g)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 14 daysLength of intraperitoneal injection course in obese mice (animal study)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026

At a glance

  • What it is / a 16-amino-acid fragment of human growth hormone, hGH 177-191 plus an N-terminal tyrosine [3]
  • FDA approval / none, for any indication [4][1]
  • Human weight-loss trial / an oral obesity trial described in a 2026 review failed to show a significant benefit [1]
  • FDA compounding status / in the 'nominated but withdrawn' table with stated safety concerns; in no category on FDA's lists [2][5]
  • Anti-doping status / WADA section S2.2.3, prohibited at all times [6]

What the human data show for someone moving to AOD-9604

A 2026 review describes a 24-week oral AOD-9604 obesity trial that failed to show a significant weight-loss benefit. The review notes the conclusion rests on sponsor-reported phase 2 results and that no peer-reviewed efficacy paper exists [1]. The same review describes a trial of an oral candidate, and no efficacy trial of injected AOD-9604 products is described [1]. There is no approved dose [1].

Animal work is not a substitute. Oral AOD9604 at 500 microgram/kg/day for 19 days cut body-weight gain in obese Zucker rats to 15.8 g against 35.6 g in controls, with higher fat-tissue lipolytic activity [7]. In obese mice, 14 days of intraperitoneal injections reduced body weight and fat, and long-term effects were not seen in mice lacking the beta-3 adrenergic receptor [8].

What people on Reddit report

Accounts from people adding this peptide to, or moving between it and, incretin drugs such as tirzepatide and semaglutide. Views on whether it works alone are mixed.

FirstBlackberry6191 · Peptides_for_Women

I'm on Tirz, have lost 20% of my weight and am 1/2 to goal. I believe the AOD is reducing my belly fat.

Says they added AOD while on tirzepatide and believe it reduces belly fat.

Read the source discussion

mrmrsdirby · Peptides_for_Women

I was thinking I needed steering away from the glp because of the loss of muscle and not exactly needing to loose more but target hit the gut with fat burning.

Original poster who was on Wegovy says they considered moving away from incretin drugs over muscle loss concerns.

Read the source discussion

What the record shows for someone moving away from it

FDA says it has identified serious adverse events that may be associated with AOD-9604, though causality is not clear, and gives no details [2]. FDA also says compounded AOD-9604 may pose a significant immunogenicity risk with certain routes of administration, from peptide impurities and characterization problems, and that it has identified no, or only limited, safety information [2]. A 2026 review of unapproved peptides notes favorable animal results across the class but scarce rigorous human safety data and potential for serious harm [9].

Regulatory status, whichever direction the switch runs

AOD-9604 is not FDA-approved for any indication [4][1]. It appears in FDA's 'nominated but withdrawn' table of bulk substances that may present significant safety risks, which holds substances previously in category 2 whose nominators withdrew them. Removal from category 2 was not a finding that it is safe [2].

It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and is not on FDA's outsourcing-facility list [10][11][5]. It is also not among the six peptides in HHS's draft enforcement-discretion policy filed October 28, 2026 [12][13].

Questions worth asking

Choose the questions you want to keep

Anti-doping status

WADA's Prohibited List names AOD-9604 and hGH 176-191 in section S2.2.3 (growth hormone fragments), prohibited at all times, in and out of competition; it is on the 2026 and 2027 Lists [6][14]. Anti-doping scientists have published urine detection methods for AOD-9604 and a stable metabolite [3].

Frequently asked questions

Are there any real user reports of switching to or from AOD-9604?
No published study, survey or case series on switching to or from AOD-9604 is available, so this page has no switching results to report. Personal accounts cannot establish what switching to or from this peptide typically does.
What does the human trial show?
A 2026 review describes a 24-week oral AOD-9604 obesity trial, with 502 people randomized, that failed to show a significant benefit on the primary weight-loss endpoint. The review notes this rests on sponsor-reported phase 2 results [1].
What safety concerns does FDA list?
FDA says it has identified serious adverse events that may be associated with AOD-9604, though causality is not clear, and that compounded AOD-9604 may pose a significant immunogenicity risk with certain routes of administration [2].
Can AOD-9604 be compounded?
It is in no category on FDA's list for state-licensed pharmacies and physicians and is not on the outsourcing-facility list [10][11]. It is not among the six peptides in HHS's October 2026 draft enforcement-discretion policy [12].
Is AOD-9604 banned in sport?
Yes. WADA names AOD-9604 and hGH 176-191 in section S2.2.3 and prohibits them at all times, in and out of competition; it is on the 2026 and 2027 Lists [6][14].

References

Show all 15 referencesHide references
  1. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475.
  2. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  3. Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-8.
  4. Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004;5(4):436-40.
  5. Bulk Drug Substances Used in Compounding Under the FD&C Act | FDA.
  6. World Anti-Doping Agency.
  7. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8.
  8. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9.
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935.
  10. U.S. Food and Drug Administration.
  11. U.S. Food and Drug Administration.
  12. Official web page.
  13. Official web page.
  14. World Anti-Doping Agency.
  15. Reddit participants. AOD 9604 (r/Peptides_for_Women). Accessed 2026-11-11.
Evidence overview for AOD-9604 Switching Reports: What Users Experience Moving To or From This Peptide